Skip to main content

Xifaxan FDA Approval History

FDA Approved: Yes (First approved May 25, 2004)
Brand name: Xifaxan
Generic name: rifaximin
Dosage form: Tablets
Company: Salix Pharmaceuticals, Inc.
Treatment for: Traveler's Diarrhea, Hepatic Encephalopathy, Irritable Bowel Syndrome

Xifaxan (rifaximin) is a nonsystemic antibiotic indicated for the treatment of patients with traveler's diarrhea caused by noninvasive strains of Escherichia coli, to reduce the risk of recurrence of hepatic encephalopathy in patients with advanced liver disease, and for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Development timeline for Xifaxan

May 27, 2015Approval FDA Approves Xifaxan (rifaximin) for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea)
Mar 25, 2010Approval FDA Approves New Use of Xifaxan for Patients with Liver Disease
May 25, 2004Approval Xifaxan Salix Pharmaceuticals, Ltd - Treatment for Travelers’ Diarrhea

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.